Gilead Sciences (GILD) Enterprise Value (2009 - 2026)

Gilead Sciences (GILD) has reported Enterprise Value for 18 consecutive years, with -$7.7 billion the latest figure, recorded in Q1 2026.

• Enterprise Value for Q1 2026 came in at -$7.7 billion, up 3.53% year-over-year; the trailing twelve-month figure through Mar 2026 was -$7.7 billion (up 3.53% YoY), and the FY2025 annual result was -$7.7 billion, up 23.41% from the prior year.
• Enterprise Value was -$7.7 billion for Q1 2026 at Gilead Sciences, roughly flat from -$7.7 billion in the prior quarter.
• Over five years, Enterprise Value peaked at -$2.9 billion in Q2 2024 and troughed at -$10.1 billion in Q4 2024.
• Average Enterprise Value over 5 years is -$6.4 billion, with a median of -$6.4 billion recorded in 2022.
• Year-over-year, Enterprise Value jumped 57.57% in 2024 and sank 85.47% in 2025.
• Over 5 years, Enterprise Value stood at -$6.4 billion in 2022, then slipped by 14.53% to -$7.3 billion in 2023, then sank by 37.11% to -$10.1 billion in 2024, then gained by 23.41% to -$7.7 billion in 2025, then fell by 0.14% to -$7.7 billion in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$7.7 billion in Q1 2026, -$7.7 billion in Q4 2025, and -$7.4 billion in Q3 2025.